Towards evidence-based response criteria for cancer immunotherapy

Towards evidence-based response criteria for cancer immunotherapy

Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature communications 2023-05, Vol.14 (1), p.3001-3001, Article 3001
Hauptverfasser: Garralda, Elena, Laurie, Scott A., Seymour, Lesley, de Vries, Elisabeth G. E.
Format: Artikel
Sprache:eng
Schlagworte:
631/67/580
692/4028/67/2321
692/4028/67/580
Cancer immunotherapy
Cancer therapies
Chemotherapy
Clinical trials
Comment
Criteria
Humanities and Social Sciences
Humans
Immunotherapy
multidisciplinary
Neoplasms - therapy
Radiomics
Response rates
Science
Science (multidisciplinary)
Solid tumors
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-023-38837-3